These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
130 related items for PubMed ID: 27761472
1. Rapid Acting Insulin Use and Persistence among Elderly Type 2 Diabetes Patients Adding RAI to Oral Antidiabetes Drug Regimens. Sambamoorthi U, Deb A, Zhou S, Garg R, Fan T, Boss A. J Diabetes Res; 2016; 2016():5374931. PubMed ID: 27761472 [Abstract] [Full Text] [Related]
5. Clinical and Economic Outcomes Associated With the Timing of Initiation of Basal Insulin in Patients With Type 2 Diabetes Mellitus Previously Treated With Oral Antidiabetes Drugs. Levin P, Zhou S, Durden E, Farr AM, Gill J, Wei W. Clin Ther; 2016 Jan 01; 38(1):110-21. PubMed ID: 26681210 [Abstract] [Full Text] [Related]
7. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia. Ushakova O, Sokolovskaya V, Morozova A, Valeeva F, Zanozina O, Sazonova O, Zhadanova E, Starceva M, Kazakova E, Saifullina M, Shapiro I, Tarasov A, Al-Tayar B, Starkova N. Clin Ther; 2007 Nov 01; 29(11):2374-84. PubMed ID: 18158078 [Abstract] [Full Text] [Related]
9. Adding Rapid-Acting Insulin or GLP-1 Receptor Agonist to Basal Insulin: Outcomes in a Community Setting. Dalal MR, Xie L, Baser O, DiGenio A. Endocr Pract; 2015 Jan 01; 21(1):68-76. PubMed ID: 25148821 [Abstract] [Full Text] [Related]
11. Predictors and Clinical Outcomes of Treatment Intensification in Patients With Type 2 Diabetes Uncontrolled on Basal Insulin in a Real-World Setting. Kallenbach L, Shui AM, Cheng WY, Fan T, Hu W, Zichlin ML, Duh MS, Ye F, Levin PA. Endocr Pract; 2018 Sep 01; 24(9):805-814. PubMed ID: 29975575 [Abstract] [Full Text] [Related]
12. Influence of baseline glycemia on outcomes with insulin glargine use in patients uncontrolled on oral agents. Banerji MA, Baron MA, Gao L, Blonde L. Postgrad Med; 2014 May 01; 126(3):111-25. PubMed ID: 24918797 [Abstract] [Full Text] [Related]
18. Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies. Xie L, Wei W, Pan C, Baser O. J Med Econ; 2013 Sep 01; 16(9):1137-45. PubMed ID: 23859434 [Abstract] [Full Text] [Related]
19. Impact of initiating insulin glargine disposable pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: a claims database analysis. Xie L, Zhou S, Pinsky BW, Buysman EK, Baser O. Diabetes Technol Ther; 2014 Sep 01; 16(9):567-75. PubMed ID: 24735083 [Abstract] [Full Text] [Related]
20. Therapeutically interchangeable? A study of real-world outcomes associated with switching basal insulin analogues among US patients with type 2 diabetes mellitus using electronic medical records data. Levin P, Wei W, Miao R, Ye F, Xie L, Baser O, Gill J. Diabetes Obes Metab; 2015 Mar 01; 17(3):245-53. PubMed ID: 25359227 [Abstract] [Full Text] [Related] Page: [Next] [New Search]